Tumor cells become more fragile when radiation hits them mid-DNA replication
For patients with advanced neuroendocrine tumors — a rare cancer whose incidence has quietly doubled over two decades — the moment when standard treatments stop working has long marked a kind of clinical horizon. Researchers presenting at the European Society for Medical Oncology Congress this week offered early evidence that pairing a DNA-synthesis inhibitor with the targeted radiopharmaceutical lutetium Lu 177 dotatate may push that horizon further out, by making tumor cells more vulnerable to radiation before it arrives. A phase 2 randomized trial, now fully enrolled across fourteen American sites, will determine whether this biological logic translates into longer lives — and whether the principle itself might open a new chapter in how medicine wields radiopharmaceuticals.
- Neuroendocrine tumor diagnoses have nearly doubled over twenty years, yet once standard therapies fail, patients face a treatment landscape with few remaining paths forward.
- The core tension is resistance: even lutetium Lu 177 dotatate, a genuine advance in the field, eventually stops working for many patients, leaving disease progression unchecked.
- The proposed solution is biological leverage — a ribonucleotide reductase inhibitor that strips tumor cells of their DNA-repair capacity, theoretically amplifying the lethal effect of the radiopharmaceutical already in use.
- Phase 1 data presented at ESMO 2025 suggested the combination is safe and carries early signs of benefit, providing enough confidence to advance to a larger, randomized test.
- A phase 2 trial has completed enrollment at 14 U.S. sites and will directly compare the combination against lutetium alone, with results that could redefine the standard of care for this patient population.
At the European Society for Medical Oncology Congress this week, researchers shared early evidence that a two-drug combination might extend survival for patients with advanced neuroendocrine tumors — a rare cancer that has long left patients with few options once initial treatments stop working.
The study, led by Aman Chauhan at the University of Miami's Sylvester Comprehensive Cancer Center, pairs a ribonucleotide reductase inhibitor with lutetium Lu 177 dotatate, a targeted radiopharmaceutical that has become standard care for certain neuroendocrine cancers. The reasoning is direct: by blocking an enzyme tumor cells depend on to copy and repair their DNA, the inhibitor leaves those cells more fragile when radiation arrives — potentially amplifying the treatment's power against tumors that have grown resistant.
Neuroendocrine tumors arise from hormone-producing cells in organs like the pancreas, stomach, and intestines. Their incidence has nearly doubled over the past twenty years, and while survival has improved overall, deaths continue to rise. Lutetium Lu 177 dotatate marked a genuine step forward, but many patients still see their disease progress — making the search for combination strategies urgent.
The phase 1 trial, funded by the National Cancer Institute, enrolled patients whose tumors had already progressed on existing treatments. Its data suggested the approach was safe and showed early signs of benefit. A phase 2 randomized trial has now completed enrollment at fourteen U.S. sites, and will compare the combination directly against lutetium alone. If the results confirm the early promise, this pairing could become a new standard for patients who have exhausted conventional options — and the underlying principle might inspire a broader wave of radiopharmaceutical combination research.
At the European Society for Medical Oncology Congress this week, researchers presented early evidence that a two-drug combination might extend survival for patients with advanced neuroendocrine tumors—a rare cancer that has long offered limited options once standard treatments stop working.
The study, led by Aman Chauhan at the University of Miami's Sylvester Comprehensive Cancer Center, tested pairing a DNA-synthesis inhibitor with lutetium Lu 177 dotatate, a targeted radiopharmaceutical that has become standard care for certain neuroendocrine cancers. The phase 1 trial, funded by the National Cancer Institute, enrolled patients whose tumors had progressed despite existing treatments. The logic behind the combination is straightforward: the DNA inhibitor should make tumor cells more vulnerable to the radiation delivered by the radiopharmaceutical, potentially amplifying the drug's killing power.
Neuroendocrine tumors are uncommon—they arise from hormone-producing cells scattered throughout the body, often in the pancreas, stomach, or intestines. For decades, treatment options were sparse. But in recent years, lutetium Lu 177 dotatate has emerged as a meaningful advance for patients whose tumors carry certain receptors. Still, many patients eventually see their disease progress. The incidence of neuroendocrine tumors has nearly doubled over the past twenty years, and while survival has improved overall, deaths from these cancers continue to climb. The need for better options is real.
Chauhan's research explores whether adding the DNA inhibitor—a ribonucleotide reductase inhibitor—can overcome that resistance. The enzyme it targets is essential for cells to copy and repair their DNA. Block it, and tumor cells exposed to radiation become more fragile. The phase 1 data suggested the approach was safe and showed early signs of benefit, enough to justify moving forward.
A phase 2 randomized trial has now completed enrollment at fourteen sites across the United States. This larger study will compare the combination directly against lutetium Lu 177 dotatate alone, measuring whether patients on the combination therapy live longer before their disease worsens. The stakes are high: if the combination proves superior, it could become a new standard for patients who have exhausted conventional treatments. Chauhan has framed this work as part of a broader shift toward theranostics—using diagnostic imaging to identify which patients will respond to which therapies, then tailoring treatment accordingly.
The research also hints at a larger strategy. If a DNA inhibitor can enhance a radiopharmaceutical's effectiveness, the same principle might apply to other drug combinations. The results, expected in the coming months or years, could reshape how oncologists approach these rare tumors and inspire a new generation of combination trials. For now, patients and their doctors are waiting to see whether this early promise translates into real survival gains.
Notable Quotes
This combination represents a novel strategy to overcome treatment resistance in gastroenteropancreatic neuroendocrine tumors.— Aman Chauhan, M.D., Sylvester Comprehensive Cancer Center
If successful, the combination could reshape the treatment landscape for these tumors and inspire further research into radiopharmaceutical combination strategies.— Aman Chauhan, M.D.
The Hearth Conversation Another angle on the story
Why does adding a DNA inhibitor to a radiopharmaceutical make sense? They seem like different tools.
They work together. The radiopharmaceutical delivers radiation directly to tumor cells. But radiation works best when cells are actively trying to copy their DNA—that's when they're most vulnerable. The DNA inhibitor keeps cells in that vulnerable state, so the radiation hits harder.
And neuroendocrine tumors are hard to treat because they're rare?
Partly that. Rarity means less research funding, less clinical experience. But also because once the standard drug stops working, there's often nothing else to reach for. These patients have exhausted their options.
How many people are we talking about?
Diagnoses have nearly doubled in twenty years. We don't have exact prevalence numbers in this data, but it's enough that researchers at major cancer centers are building entire programs around it.
What happens if the phase 2 trial works?
It becomes a new standard option for patients whose disease has progressed. But more than that—it opens a door. If this combination works, oncologists will start asking: what other radiopharmaceuticals could be enhanced this way? What other DNA inhibitors might work? You get a whole new class of treatments.
And if it doesn't work?
Then you've learned something too. You know this particular pairing doesn't help, and you move on to the next idea. But the researchers seem confident enough to have already enrolled hundreds of patients in phase 2.